Back A A A Font Size Receive E-mail Alerts Press Releases

MicroPort® CardioFlow Attends CSI Asia-Pacific 2019


Guangzhou, China – On February 22 to 24, 2019, the CSI Asia-Pacific 2019 congress took place in Guangzhou, China. The congress gave a comprehensive review and outlook of major topics in the application and development of interventional therapy for congenital, structural and valvar heart disease and gathered over 400 healthcare professionals and researchers from across the world. MicroPort Shanghai CardioFlow Medtech Co., Ltd. ("MicroPort® CardioFlow") presented at the congress the independently developed VitaFlow® Transcatheter Aortic Valve and Delivery System ("VitaFlow®") and VitaFlow® II Transcatheter Aortic Valve and Recapturable Delivery System ("VitaFlow® II"), which drew huge attention.
On February 23 afternoon, MicroPort® CardioFlow presented in cooperation with the TAVR team of Zhongshan Hospital Affiliated to Fudan University a live case using VitaFlow® II. A TAV27 valve was chosen for this patient, and the procedure went quite successfully. After the valve deployment, the echocardiography and angiography showed that pressure gradient was 0mmHg with was no paravalvular leak and no aortic regurgitation. The procedure delivered outstanding clinical result. During the live case, the healthcare professionals present at the congress and the physicians in the operating room had heated discussions and they all agreed on the post-operative effectiveness of VitaFlow® II. During the congress, MicroPort® CardioFlow also had exchanges with healthcare professionals from all of the world on the current state of valvular disease treatment and the development of medical device technologies. The healthcare professionals highly recognized the significant efficacy and performance of MicroPort® CardioFlow’s VitaFlow® for bicuspid ASS patients.
MicroPort® CardioFlow’s VitaFlow® II inherits the unique motorized handle design of VitaFlow®. It can be completely recaptured before 75% deployment. The reinforced inner and outer shafts still retain flexibility and can be bent 360 degrees. The product also innovatively introduces the integrated sheath to widen the range of the sizes of access artery and effectively reduces the incidence rate of vascular complications. In addition, VitaFlow® II is accompanied with balloon dilation catheter and introducer set to provide the patients suffering severe aortic stenosis and doctors with a comprehensive integrated therapeutic solution. As a result, the safety and efficacy of the procedure are increased. Thus far, the product has successfully applied for and entered the special review and approval procedure for innovative medical devices with the National Medical Products Administration (NMPA), known as the Green Path, which is expected to reduce its time to market and benefit more domestic patients suffering severe aortic stenosis as soon as possible.

About MicroPort®

MicroPort Scientific Corporation (the "Group") is a leading medical device company with business focusing on innovating, manufacturing, and marketing high-quality and high-end medical devices globally. With a diverse portfolio of products now being used at an average rate of one for every 8 seconds in thousands of major hospitals around the world, the Group maintains world-wide operations in a broad range of business segments including Cardiovascular, Orthopedic, Cardiac Rhythm Management, Electrophysiological, Endovascular, Neurovascular, Surgical, Diabetes Care and Endocrinal Management, and others. MicroPort® is dedicated to bringing about a people-centric SuperCluster of emerging medical technologies to provide the best yet accessible ways & means to prolong and reshape lives.

For more information, please refer to:

Forward-Looking Statements

Some information contained on this website contains forward-looking statements. These forward-looking statements include, without limitation, those regarding our future financial position, our strategy, plans, objectives, goals and targets, future developments in the markets where we participate or are seeking to participate, and any statements preceded by, followed by or that include the words "believe", "intend", "expect", anticipate", "project", "estimate", "predict", "is confident", "has confidence" and similar expressions are also intended to identify forward-looking statements. Such statements are based upon the current beliefs and expectations of MicroPort®'s management and are subject to significant risks and uncertainties. MicroPort Scientific Corporation undertakes no obligation to update any of the statements. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors that could cause actual future results to differ materially from current expectations include, but are not limited to, general industry and economic conditions, PRC governmental policies and regulations relating to the medical device manufacturing industry, competition in the medical device manufacturing industry, our ability to develop new products and stay abreast of market trends and technological advances, our goals and strategies, our ability to execute strategic acquisitions of, investments in or alliances with other companies and businesses, fluctuations in general economic and business conditions in China.

This document is for information purposes only and does not constitute or form part of any offer or invitation to sell or the solicitation of an offer or invitation to purchase or subscribe for any securities of MicroPort Scientific Corporation, and no part of it shall form the basis of, or be relied upon in connection with, any agreement, arrangement, contract, commitment or investment decision in relation thereto whatsoever.

All rights reserved.
Copyright © 1998-2019 MicroPort Scientific Corporation

Leanne Li
Board Secretary and Vice President of Corporate General Affairs
MicroPort Scientific Corporation
Tel: (86)(21) 38954600-6957


[Prev]:MicroPort® Announces Successful Non-Inferior Two-Year Clinical Data for its Firehawk Drug-eluting Stent at EuroPCR 2019
[Next]:The First Edition of MicroPort® Master Course Complex PCI Cross-Regional Program Ends Successfully